Annovis Bio CEO letter details Phase II/III AD data; will narrow enrollment to early-stage patients for next trial

Annovis Bio, Inc.

Phase II/III study in MMSE 21-24 patients: buntanetap showed ADAS-Cog11 improvement of -2.36 vs placebo at 3 months.
In moderate AD (MMSE 14-20), improvement was -0.65 vs placebo +1.79, indicating high placebo effect.
Next Phase III will prescreen for plasma AD biomarkers and enroll only early/mild AD (MMSE 21-28).
CEO states FDA will accept buntanetap for symptomatic relief and allow continuation for disease-modification study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.